City of Hope

DxTerity aims to develop a genomic blood test to identify which cancer patients are most likely to benefit from radiation therapy or are at risk for toxicity.

In individuals diagnosed with prostate cancer before the age of 45, researchers saw enhanced expression of immune- and inflammation-related genes.

As part of the deal, TGen will also become a subsidiary of City of Hope's parent organization, but will remain a non-profit headquartered in Arizona.

Researchers will study how prior hypoglycemic episodes can result in the "metabolic memory" of persistent vascular complications.